WuXi Biologics Sets New Standards at Hong Kong ESG Awards 2025

WuXi Biologics Recognized at Hong Kong ESG Reporting Awards 2025

WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has recently achieved a significant milestone by winning the Outstanding ESG Disclosure award at the Hong Kong ESG Reporting Awards (HERA) 2025. This recognition reinforces the company's commitment to sustainable practices and transparent operations in the biologics sector, pushing the boundaries of what it means to be environmentally and socially responsible.

The Outstanding ESG Disclosure award is a testament to WuXi Biologics' ongoing dedication to maintaining high standards in environmental, social, and governance (ESG) reporting. The company’s engagement in this area was previously acknowledged through last year's ESG Report Benchmark Award from HERA, validating their consistent efforts in ESG practices. As the world increasingly prioritizes corporate responsibility, such recognition is not just an accolade but a crucial element for building trust among clients, investors, regulators, and other key stakeholders.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of the ESG Committee, emphasized the importance of transparency in fostering trust and collaboration within the industry. He stated, "Transparency is the cornerstone of trust. We firmly believe that openly sharing our ESG journey is essential, because only through collaboration can we help to create lasting value that contributes positively to society and the environment." His remarks underline the company's commitment to surpassing expectations and leading the industry toward a sustainable future.

WuXi Biologics understands that in today's ultra-competitive business landscape, effective ESG strategies can serve as a significant competitive advantage. Their detailed and accountable ESG reporting, which includes sustainability targets such as corporate governance, talent development, and greenhouse gas (GHG) emissions reduction, acts as reassurance to stakeholders that the company is genuinely driving impactful changes within the industry.

Participating in initiatives like the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics exemplifies its proactive stance on sustainability through participation and recognition. Their accolades include an MSCI AAA rating, an EcoVadis Platinum Medal, listings on the Dow Jones Sustainability Indices (DJSI), and being recognized on the CDP "A List" for climate change and water security. This consistent performance has led to the company being rated as an industry leader in ESG practices by Sustainalytics for five consecutive years.

With over 12,000 talented employees operating across several regions, including the United States, China, Ireland, Germany, and Singapore, WuXi Biologics employs cutting-edge technologies to enhance efficiency and reduce costs in the production of biologics. As of mid-2025, the company is actively supporting 864 integrated client projects, with a notable 24 held in commercial manufacturing, demonstrating their influence and commitment across the industry.

WuXi Biologics firmly believes that sustainability is a critical driver for long-term business success. Through continuous innovation in green technology, the company aims to provide advanced and comprehensive Green CRDMO solutions for its global partners. By fostering collaboration across all stakeholder groups, they are committed to creating shared value, promoting responsible practices, and generating positive social and environmental impacts. WuXi Biologics is not just about making profits; they are dedicated to nurturing a healthier planet and a better society.

As the awareness of corporate responsibility grows, WuXi Biologics stands as a role model for organizations aiming to merge profitability with purpose. The recognition at the Hong Kong ESG Reporting Awards signifies more than just an award; it showcases the potential for businesses to strive for excellence while making substantial contributions to a sustainable future that benefits all of humanity.

For more information about WuXi Biologics and its commitment to sustainability, visit www.wuxibiologics.com.